Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCAB NASDAQ:CVKD OTCMKTS:CVSI NASDAQ:MIRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCABBioAtla$0.77+0.1%$0.42$0.24▼$2.53$45.46M0.92939,867 shs1.60 million shsCVKDCadrenal Therapeutics$13.15-2.6%$12.12$8.74▼$22.90$27.63M0.9523,942 shs18,990 shsCVSICV Sciences$0.03+5.5%$0.04$0.02▼$0.05$6.08M0.6592,741 shs125,124 shsMIRAMIRA Pharmaceuticals$1.45-12.7%$1.50$0.73▼$2.56$31.66M1.75190,460 shs1.12 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCABBioAtla+0.10%+44.44%+97.48%+91.10%-56.71%CVKDCadrenal Therapeutics-2.59%-0.68%+12.59%-5.12%+58.05%CVSICV Sciences+5.47%+3.27%-11.03%+17.63%-23.74%MIRAMIRA Pharmaceuticals-12.65%+3.57%-2.68%+19.83%+2.84%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCABBioAtla$0.77+0.1%$0.42$0.24▼$2.53$45.46M0.92939,867 shs1.60 million shsCVKDCadrenal Therapeutics$13.15-2.6%$12.12$8.74▼$22.90$27.63M0.9523,942 shs18,990 shsCVSICV Sciences$0.03+5.5%$0.04$0.02▼$0.05$6.08M0.6592,741 shs125,124 shsMIRAMIRA Pharmaceuticals$1.45-12.7%$1.50$0.73▼$2.56$31.66M1.75190,460 shs1.12 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCABBioAtla+0.10%+44.44%+97.48%+91.10%-56.71%CVKDCadrenal Therapeutics-2.59%-0.68%+12.59%-5.12%+58.05%CVSICV Sciences+5.47%+3.27%-11.03%+17.63%-23.74%MIRAMIRA Pharmaceuticals-12.65%+3.57%-2.68%+19.83%+2.84%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCABBioAtla 2.00Hold$5.00545.24% UpsideCVKDCadrenal Therapeutics 3.00Buy$32.00143.35% UpsideCVSICV Sciences 0.00N/AN/AN/AMIRAMIRA Pharmaceuticals 3.50Strong Buy$17.001,072.41% UpsideCurrent Analyst Ratings BreakdownLatest CVSI, BCAB, CVKD, and MIRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/13/2025BCABBioAtlaJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform8/13/2025BCABBioAtlaCitizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCABBioAtla$11M4.14N/AN/A$0.25 per share3.10CVKDCadrenal TherapeuticsN/AN/AN/AN/A$4.17 per shareN/ACVSICV Sciences$15.70M0.41N/AN/A$0.01 per share3.47MIRAMIRA PharmaceuticalsN/AN/AN/AN/A$0.13 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCABBioAtla-$69.78M-$1.10N/AN/AN/AN/A-1,177.18%-137.51%11/6/2025 (Estimated)CVKDCadrenal Therapeutics-$10.65M-$8.88N/AN/AN/AN/A-265.37%-196.38%11/6/2025 (Estimated)CVSICV Sciences-$2.39MN/A0.00∞N/A-10.36%-80.82%-19.38%N/AMIRAMIRA Pharmaceuticals-$7.85M-$0.49N/AN/AN/AN/A-406.70%-328.44%11/11/2025 (Estimated)Latest CVSI, BCAB, CVKD, and MIRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025MIRAMIRA Pharmaceuticals-$0.11-$0.09+$0.02-$0.09N/AN/A8/11/2025Q2 2025CVKDCadrenal Therapeutics-$1.60-$1.87-$0.27-$1.87N/AN/A8/7/2025Q2 2025BCABBioAtla-$0.29-$0.31-$0.02-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCABBioAtlaN/AN/AN/AN/AN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/AN/ACVSICV SciencesN/AN/AN/AN/AN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCABBioAtlaN/A1.241.24CVKDCadrenal TherapeuticsN/A3.553.55CVSICV Sciences0.121.040.30MIRAMIRA PharmaceuticalsN/A2.802.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCABBioAtla77.23%CVKDCadrenal Therapeutics7.92%CVSICV SciencesN/AMIRAMIRA Pharmaceuticals35.16%Insider OwnershipCompanyInsider OwnershipBCABBioAtla11.22%CVKDCadrenal Therapeutics26.09%CVSICV Sciences3.80%MIRAMIRA Pharmaceuticals6.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCABBioAtla6058.72 million52.13 millionOptionableCVKDCadrenal Therapeutics42.05 million1.51 millionNot OptionableCVSICV Sciences70184.79 million177.77 millionNot OptionableMIRAMIRA Pharmaceuticals219.07 million17.80 millionNot OptionableCVSI, BCAB, CVKD, and MIRA HeadlinesRecent News About These CompaniesMira Pharmaceuticals shareholders approve acquisition of SKNY PharmaceuticalsSeptember 12 at 1:42 PM | msn.comMIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking CessationSeptember 12 at 7:30 AM | accessnewswire.comAMIRA Pharmaceuticals Approves 2022 Omnibus Incentive PlanSeptember 11 at 5:51 PM | tipranks.comWall Street Zen Downgrades MIRA Pharmaceuticals (NASDAQ:MIRA) to SellSeptember 7, 2025 | americanbankingnews.comMira Pharmaceuticals completes Phase 1 SAD portion for oral Ketamir-2August 20, 2025 | msn.comMIRA Pharmaceuticals Completes Phase 1 Trial for Ketamir-2August 19, 2025 | tipranks.comMIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose StageAugust 19, 2025 | accessnewswire.comAMIRA Pharmaceuticals’ Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus ...August 14, 2025 | dispatch.comMIRA Pharmaceuticals’ Ketamir-2 Shows Promising Preclinical ResultsAugust 12, 2025 | msn.comMira announces acceptance of second Ketamir-2 manuscript for publicationAugust 12, 2025 | msn.comMIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine ...August 12, 2025 | finance.yahoo.comMIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or PregabalinAugust 12, 2025 | accessnewswire.comAMIRA Pharmaceuticals Announces Virtual Annual Meeting to Discuss SKNY MergerAugust 9, 2025 | msn.comMIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain StudyJuly 30, 2025 | accessnewswire.comAMIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic PainJuly 29, 2025 | accessnewswire.comAMIRA Pharmaceuticals Gets FDA Clearance for Ketamir-2 TrialsJuly 28, 2025 | tipranks.comMIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for ...July 11, 2025 | sacbee.comSMIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for AcquisitionJuly 11, 2025 | accessnewswire.comAMIRA Pharmaceuticals Reports Promising SKNY-1 Preclinical ResultsJuly 10, 2025 | tipranks.comCannabinoid Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightJuly 10, 2025 | uk.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCVSI, BCAB, CVKD, and MIRA Company DescriptionsBioAtla NASDAQ:BCAB$0.77 +0.00 (+0.10%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.79 +0.01 (+1.43%) As of 09/12/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.Cadrenal Therapeutics NASDAQ:CVKD$13.15 -0.35 (-2.59%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$13.55 +0.40 (+3.04%) As of 09/12/2025 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.CV Sciences OTCMKTS:CVSI$0.03 +0.00 (+5.47%) As of 09/12/2025 03:54 PM EasternCV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.MIRA Pharmaceuticals NASDAQ:MIRA$1.45 -0.21 (-12.65%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.48 +0.03 (+2.07%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
